Biogen Q4 Earnings Review: Why I'm Calling Time On This 'Powder Puff' Pharma
Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...
pharmaphorum2d
Sage, Biogen's zuranolone looks approvable, but will it sell?
Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...
pharmaphorum2d
Biogen bags rights to epilepsy drug from Stoke in $550m deal
Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from ...
BioPharma Dive3d
Biogen buys rights to Stoke’s rare epilepsy drug
In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...
Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy
Under the terms of the deal, Bedford, Mass.-based Stoke STOK will retain exclusive rights for the treatment called ...
STAT3d
Biogen partners with Stoke Therapeutics on drug for severe epilepsy
Biogen and Stoke Therapeutics have signed a deal to co-develop and sell Stoke’s experimental drug for Dravet syndrome, ...
Biogen continues dealmaking buzz with Stoke Therapeutics
Stoke Therapeutics Inc. (Nasdaq: STOK) has pulled in Biogen (Nasdaq: BIIB) to help it develop and commercialize a treatment ...
BioSpace3d
Biogen and Stoke Strike Dravet Syndrome Co-Development Deal
The partnership splits the rights to Stoke’s epilepsy antisense oligonucleotide, with up to $385 million in potential ...
Biogen, Stoke Therapeutics Set Dravet Syndrome Collaboration
Biogen and Stoke Therapeutics have agreed to collaborate on Stoke's proposed zorevunersen treatment for the severe genetic epilepsy Dravet syndrome in a deal potentially worth hundreds of millions of ...